Faculty

Institution

Unit

Venue

David M. Gershenson

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Gynecologic Oncology And Reproductive Medicine

Department Of Gynecologic Research

The University of Texas MD Anderson Cancer Center

David M. Gershenson is a Senior Professor at The University of Texas MD Anderson Cancer Center. A leading figure in gynecologic oncology, his research focuses on rare epithelial ovarian carcinomas, low-grade serous carcinoma, and sex cord-stromal tumors. His recent work includes a 2025 Nature publication on PPP2R1A mutations and immunotherapy survival, plus trials on novel regimens (BOUQUET) and targeted therapies (ribociclib plus letrozole). He also investigates molecular biomarkers, including TP53/KRAS co-mutations, to refine treatment strategies and improve survival outcomes.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

David M. Gershenson

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

gynecologic oncology gynecology oncology ovarian cancer gynecologic cancers cancer treatment pathology cancer research cancer care cancer management radiation oncology cancer biology tumor biology oncogenes cancer cells surgical oncology gynecological surgery tumoral pathology obstetrics and gynaecology malignant disease molecular cancer surgical pathology reproductive medicine cancer genetics endocrine-related cancers medicine cervical cancer cancer genomics endocrine oncology intraoperative consultation cancer discovery reproductive health carcinogenesis medicinal research anti-cancer agents histopathology molecular pathology clinical research tumor targeting tumor heterogeneity pharmacotherapy obstetrics cancer growth tumor suppressors urogynecology low malignant potential therapeutic efficacy clinical endpoint epithelial ovarian cancer vascular biology endometrial cancer phase ii trial ovarian hormones cancer risk low-grade serous carcinoma germ cells novel therapies ovarian carcinoma breast oncology metronomic chemotherapy female reproductive system advanced ovarian cancer treatment options radiation therapy colorectal cancer ovarian cancer cells fallopian tube prognostic factors sex cord-stromal tumors borderline ovarian tumors lymphoid neoplasia endometrial carcinoma peritoneal cancer genitourinary cancers serous ovarian carcinoma tumor growth

Notable Scholarly Works

Notable Federal Grants

Collaborators

69O Novel Regimens for Persistent/Recurrent Rare Epithelial Ovarian Carcinomas (Eocs) Selected According to Biomarker Status: Engot-Gyn2/Gog-3051/Bouquet Phase II Study Results. ESMO Open (2025)

pathologynovel regimensoncologycancer letterovarian cancerbiomarker statusendocrine-related cancersgynecologic cancersgynecologic oncologygynecologyendocrine oncology

Abstract 4081: Analysis of Low-Grade Serous Ovarian Cancer by Long-Read Full Length Transcripts Sequencing. Cancer Research (2025)

geneticspathologymolecular diagnosticsoncologytumor heterogeneitycancer genomicsovarian cancerabstract 4081gynecologic cancersgynecologic oncologygynecology

Author Correction: Ppp2r1a Mutations Portend Improved Survival After Cancer Immunotherapy. Nature (2025)

pathologymolecular cancermedicineoncogenesmolecular medicinecancer researchoncologycancer genomicscancer geneticsauthor correction

Controversies in the Management of Rare Gynecologic Cancers. International Journal of Gynecological Cancer (2025)

cancer managementgynecological surgeryoncologyrare gynecologic cancerscancer careendocrine-related cancersgynecologic cancersgynecologic oncologygynecology

Controversies in the Organization and Structure of Management for Rare Tumors. International Journal of Gynecological Cancer (2025)

cancer managementpathologycancer treatmentrare tumorscancer researchoncologymalignant diseasesurgical oncologyradiation oncologycancer care

Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitors in Preclinical Adult-Type Ovarian Granulosa Cell Tumor Models. SSRN Electronic Journal (2025)

pharmacologycancer biologymolecular cancercancer treatmentcancer cellsoncogenescyclin-dependent kinase 4/6oncologyovarian canceranti-cancer agentstumor biologycell biologygynecologic cancersgynecologic oncologygynecologytherapeutic targets

Final Overall Survival Results From the Gog281/Logs Study Evaluating Trametinib Versus Physician’s Choice Standard-Of-Care Therapy for Recurrent Low-Grade Serous Ovarian Cancer (Lgsoc). International Journal of Gynecological Cancer (2025)

cancer treatmentoncologyclinical endpointsurvival analysisovarian cancercancer caregynecologic cancersgynecologic oncologygynecology

Molecular Profiling and Tumor Biomarker Analysis of Gog281/Logs: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma. Clinical Cancer Research (2025)

oncogenesmolecular diagnosticsbiomarkerscancer genomicsovarian cancergynecologic cancersgynecologic oncologygynecology

Ovarian Low-Grade and High-Grade Serous Carcinoma as a Synchronous or Metachronous Phenomenon: A Cohort of 30 Cases. Gynecologic Oncology (2025)

ovarian low-gradepathologytumoral pathologyhigh-grade serous carcinomasurgical pathologymetachronous phenomenononcologymalignant diseaseovarian cancergynecologic cancersgynecologic oncologygynecology

Ovarian Mixed Low- and High-Grade Serous Carcinoma as a Synchronous or Metachronous Phenomenon: A Clinicopathologic Study of 39 Cases. Gynecologic Oncology (2025)

pathologytumoral pathologyhigh-grade serous carcinomaanatomical pathologysurgical pathologyintraoperative consultationmetachronous phenomenononcologymalignant diseaseovarian cancerclinicopathologic studygynecologic cancersgynecologic oncologygynecology

1
2
3
4
5
59
10 / page

David M. Gershenson

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Gynecologic Oncology And Reproductive Medicine

Department Of Gynecologic Research

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

David M. Gershenson

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

69O Novel Regimens for Persistent/Recurrent Rare Epithelial Ovarian Carcinomas (Eocs) Selected According to Biomarker Status: Engot-Gyn2/Gog-3051/Bouquet Phase II Study Results. ESMO Open (2025)

pathologynovel regimensoncologycancer letterovarian cancerbiomarker statusendocrine-related cancersgynecologic cancersgynecologic oncologygynecologyendocrine oncology

Abstract 4081: Analysis of Low-Grade Serous Ovarian Cancer by Long-Read Full Length Transcripts Sequencing. Cancer Research (2025)

geneticspathologymolecular diagnosticsoncologytumor heterogeneitycancer genomicsovarian cancerabstract 4081gynecologic cancersgynecologic oncologygynecology

Author Correction: Ppp2r1a Mutations Portend Improved Survival After Cancer Immunotherapy. Nature (2025)

pathologymolecular cancermedicineoncogenesmolecular medicinecancer researchoncologycancer genomicscancer geneticsauthor correction

Controversies in the Management of Rare Gynecologic Cancers. International Journal of Gynecological Cancer (2025)

cancer managementgynecological surgeryoncologyrare gynecologic cancerscancer careendocrine-related cancersgynecologic cancersgynecologic oncologygynecology

Controversies in the Organization and Structure of Management for Rare Tumors. International Journal of Gynecological Cancer (2025)

cancer managementpathologycancer treatmentrare tumorscancer researchoncologymalignant diseasesurgical oncologyradiation oncologycancer care

Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitors in Preclinical Adult-Type Ovarian Granulosa Cell Tumor Models. SSRN Electronic Journal (2025)

cancer treatmentoncologyclinical endpointsurvival analysisovarian cancercancer caregynecologic cancersgynecologic oncologygynecology

oncogenesmolecular diagnosticsbiomarkerscancer genomicsovarian cancergynecologic cancersgynecologic oncologygynecology

Ovarian Low-Grade and High-Grade Serous Carcinoma as a Synchronous or Metachronous Phenomenon: A Cohort of 30 Cases. Gynecologic Oncology (2025)

ovarian low-gradepathologytumoral pathologyhigh-grade serous carcinomasurgical pathologymetachronous phenomenononcologymalignant diseaseovarian cancergynecologic cancersgynecologic oncologygynecology

Ovarian Mixed Low- and High-Grade Serous Carcinoma as a Synchronous or Metachronous Phenomenon: A Clinicopathologic Study of 39 Cases. Gynecologic Oncology (2025)

1
2
3
4
5
59
10 / page